HMG: aminoglycoside antibiotics may be expected to treat human dementia

January 16, 2020 / biogenic Valley / recently, a research report published in the international journal human molecular genetics was summarized Researchers from the University of Kentucky School of Medicine found that aminoglycosides may help treat frontotemporal dementia through a concept validation study Photo source: mark Cornelison / UK frontotemporal dementia is the second most common human dementia after Alzheimer's disease It is also the most common early dementia, which usually occurs between the age of 40-65 It will affect the frontal and temporal parts of the brain, resulting in behavioral changes, speech and writing difficulties, and memory loss The researchers say that a specific gene mutation, or a specific protein called progranulin, is carried by a group of patients with frontotemporal dementia Although the protein is not widely understood, its deletion is related to disease development In this study, the researchers found that when aminoglycoside antibiotics were added to the neuron cells carrying the mutation of granulin precursor, the cells would jump to produce the full length of granulin precursor Researchers Matthew gentry said that these patients' brain cells usually carry this mutation, which can inhibit the formation of granin precursors By adding small antibiotic molecules to neurons, they can trick cells to make granin precursors In addition, the researchers also found that both gentamicin and G418 antibiotics can effectively repair the mutation, and produce functional granulin precursor protein When either of the two antibiotics is added to the affected cells, the level of granulin precursor will recover by about 50% - 60% The results are very important for the development of new therapies for frontotemporal dementia Next, the researchers will further study the therapeutic effect of these antibiotics on mice carrying the mutation (causing frontotemporal dementia) In addition, the researchers hope to develop new compounds based on gentamicin and G418 to treat frontotemporal dementia more safely and effectively, although gentamicin is an FDA However, due to many side effects, the clinical application of the approved drugs is still limited Finally, researcher Zhu said that if we can find the right resources and cooperate with clinicians, we may be able to redirect the drug Of course, at present, it is only at the early stage of the study Based on the results of the early study, we will further explore whether aminoglycoside antibiotics or their derivatives can help to effectively develop a new type of frontotemporal dementia treatment Treatment Original sources: Lisha Kuang, Kei Hashimoto, Eric J Huang, et al Frontotemporal dementia nonsense station of progranulin recovered by aminoglycosides, human molecular genetics (2019) Doi: 10.1093/hmg/ddz280